Dicerna’s pipeline of RNAi-targeted drugs and delivery systems is focused primarily in the therapeutic areas of oncology and metabolic diseases. In addition to these internal focus areas, Dicerna expects to broadly utilize its Dicer Substrate Technology in several other therapeutic areas, such as inflammation, immunology, cardiovascular diseases, and others, through collaborations with pharmaceutical and biotechnology companies.
James Jenson, CEO and co-founder of Dicerna Pharmaceuticals, said: “Dicer Substrate Technology represents a second generation of gene silencing that can generate drug candidates with greater potency and longer duration of action than earlier RNAi approaches, because of the distinct way in which it engages this important biological pathway.
“The exclusive right to sublicense the full portfolio of Dicer Substrate Technology puts us in an even stronger position to leverage the development of RNAi-based therapeutics and advance our business strategy.”